The records of the Phenylketonuria Register were examined to determine the factors associated with early intellectual progress in children who had received a diet low in phenylalanine from soon after birth. A total of 1031 children were born between 1964 and 1980 and started treatment before they were 4 months of age, and 808 of them were followed up prospectively. 
Children with phenylketonuria caused by phenylalanine hydroxylase deficiency seem to develop normally if they receive a low phenylalanine diet from soon after birth. Most published studies have reported mean intelligence quotients (IQ) of about 100, and have come to optimistic conclusions concerning the response to treatment. ' 2 Children who are treated early, however, tend to have IQs below those of their first degree relatives3 4 and an educational performance inferior to their siblings.4 5 They also have an increased incidence of abnormal behaviour.6 7 These data suggest that mild neurological impairment occurs in children with phenylketonuria despite early treatment.7 '8 We have reviewed the progress of 4 year olds with phenylketonuria born in the United Kingdom between 1964 and 1980 who were treated early and followed up by the Phenylketonuria Register.A9 Their IQs have been compared with IQ norms that were revised to take account of the increase in population IQ scores,'0 which seems to be occurring at about the same rate in all developed nations," including the United Kingdom.'2 1' In the children with phenylketonuria the associations between IQ and various aspects of diagnosis and treatment have been investigated to try and identify any that may influence outcome and providing guidelines for management.
Subjects and methods

THE PHENYLKETONURIA REGISTER
The register maintains a national list with diagnostic details of all subjects with phenylketonuria (defined as phenylalanine concentrations persistently above 480 ,tmol/1) born from 1964 onwards. 14 Two national surveys were conducted (in 1972 and 1980) to ensure that the register was complete. From the mid 1960s onwards a national programme of routine screening of urine for phenylketonuria between 3 and 6 weeks of age was progressively replaced by a system of blood testing between the 6th and 14th days'4; the change was virtually complete by 1971 . For this reason we have distinguished between children born from 1964 to 1971 (cohort 1) and those born from 1972 to 1980 (cohort 2).
The identification of subjects on the register and the protocol used for prospective follow up have been described previously.6 8 9 14 Measurement of IQ was requested within three months of the fourth birthday using the Stanford-Binet test (short form L-M, 1932 standardisation, 1960 revision). The StanfordBinet test was standardised again in 197210 but to maintain consistency the original standardisation was adhered to throughout the study. The computation of IQs was checked by the staff of the register and corrected where necessary.
CRITERA FOR INCLUSION OF SUBJECTS
The register has on record 1031 subjects born between 1964 and 1980 who were detected by routine testing (urine or blood) and had started long term treatment with a diet low in phenylalanine before 120 days of age (table 1) . Children who were treated for less than one year because they had mild phenylketonuria, and those with defects of biopterin metabolism, were excluded. In all, 808 children completed the recommended follow up protocol (table 1) . Twenty three had stopped the diet before the fourth birthday, 11 because they had a mild form of phenylketonuria (blood phenylalanine concentrations 600-900 j,mol/I on a normal diet), and 12 because treatment lapsed (blood The method of diagnosis (urine or blood testing), whether or not the phenylalanine concentrations at diagnosis were above 1200 ,umol/l, and the age in days at the start of treatment were recorded for every patient: quantitative measurements of diagnostic plasma phenylalanine concentrations were available in 85% of subjects. Serial blood phenylalanine concentrations during treatment were categorised and plotted as described previously,6 17 and the average phenylalanine concentrations (area under the curve divided by time) were calculated for the period from the start of treatment to the fourth birthday. Periods of unusually low phenylalanine concentrations were assessed by calculating the total length of time during which the plot of phenylalanine concentrations remained below 120 iimol/l during the first 2 years of life; after 2 years of age few measurements were below 120
[tmol/l. The association between IQ SD score at the age of 4 years and demographic, diagnostic, and treatment variables was explored in a series of tables. As many of the variables were correlated, multiple regression was used to assess their independent effects upon IQ SD score. There were missing values for some variables, notably quantitative phenylalanine measurements at diagnosis, so that the tables do not all refer to exactly the same number of subjects. ,tmol/l in the first 2 years of life, and social class) Average phenylalanine concentration (umoI/I) Mean IQ SD scores and 95% confidence intervals compared with average phenylalanine control between the start of treatment and thefourth birthday, adjustedfor other variables by regression.
Results
TEMPORAL CHANGES IN SCREENING AND IN IQ
were examined hy multiple regression (table 5) .
Preliminary analyses had shown that method of diagnosis was not significant in either cohort once these five covariates had been taken into account (adjusted mean differences in IQ SD scores between subjects urine diagnosed by blood tests were 0 13 in cohort 1, (p=0 42) and 0 04 in cohort 2, p=0 93). Birth year (which had no effect in cohort 2) was still significant in cohort 1 when the other variables were accounted for. After adjustment for the other variables the estimated annual rise in IQ SD scores fell from 0-126 (1-9 IQ points)/year (p=00005) to 0-084 (1-3 IQ points) (p=0-014)/ year, and addition of birth year to the analysis somewhat reduced the effects of age at the start of treatment and of low phenylalanine concentrations (making the latter not a significant variable). Birth year, however, had negligible effects on the other measurements and, as it was not significant in cohort 2, it was decided to omit it from the regression analyses. In cohort 1 a more negative IQ SD score was independently and significantly associated with each of the variables included in the analysis (table 5) and the relationships were not significantly different from linear. In cohort 2, despite the higher mean IQ, the results were strikingly similar except that IQ SD scores showed no association with higher phenylalanine concentrations at diagnosis. There were no significant interactions between the variables in either cohort. When the analysis was repeated with the two cohorts combined (adding a variable to distinguish them) the results were similar, although being in cohort 1 was still associated with a worse outcome (actual difference in IQ SD score 0 407, adjusted difference 0-263, p=00026); there was, as could be expected, significant interaction between diagnostic phenylalanine concentrations and birth cohort (p=001) but not between birth cohort and any other variables.
The influence of average phenylalanine control on IQ SD scores in cohorts 1 and 2, adjusted using least square means for the effects of four other covariates, is illustrated in the figure. The trends were similar and not significantly different from linear. Subjects with the 'worst' dietary control (average phenylalanine concentrations >800 [tmol/l) had mean IQs over 1 SD below those in subjects with the 'best' control (average phenylalanine concentrations <301 ,tmol/l).
Less than 10% of subjects in either cohort had all the most favourable diagnostic and treatment characteristics (diet before 21 days of age, average phenylalanine concentrations below 400 ,umol/l, and periods of low phenylalanine concentrations lasting less than two months). In those who did (16 in cohort 1, and 46 in cohort 2), after standardising for social class, mean IQ was 100 in cohort 1 and 112 6 in cohort 2. The mean IQs in the same groups of children predicted by the regression equations were 104 and 112-6, respectively, compared with IQ norms of 109-8 and 112-4. Thus in cohort 1, even children who received the 'best treatment' had IQs well below the population norms and did much worse than similar children in cohort 2, who seemed to achieve optimal scores.
Discussion
Interpretation of the IQ results in the present study depends to some extent on the assumptions made concerning the trends in IQ scores in the general population. There is good evidence that in the United Kingdom children's IQ scores have been rising steadily (P Fuggle, I Smith, unpublished observations), just as in the United States.'2 13 15 Although the method we have used to allow for population IQ trends is only an approximation, it has the merit of emphasising low a rise in population IQ scores above 100 may lead to over optimistic interpretation of IQ data in children at risk. It also explains why children with phenylketonuria who are treated early, despite having apparently 'normal' IQs, also have cognitive deficits,20 21 educational difficulties,4 5 and an increased incidence of behavioural problems, notably hyperactivity. 6 7 In children treated early and born in the mid 60s, mean IQ was-over 1 SD (16 points) below the revised norms, and even in children born in the late 70s the mean IQ was still 0-5 SD (8 points) below the norms. It should be emphasised that the reduction was the result of a general shift downwards in scores, rather than to the presence of a minority of children with particularly low IQs. A total of 19% of children born between 1964 and 1971, and 8% of those born in the mid 70s, had IQs more than 2 SD below the norms. Such children are likely to experience serious educational and employment problems. Had the usual figure of 70 been taken as the bottom limit of normal, only 7% and 2%, respectively, would have been considered to be in this group. As children excluded from our study seem to have done rather worse we may have underestimated the size of the problem.
The study did not fully explain why, nationwide, children born in the 60s did so much worse than children born in the 70s, although a later start to treatment and more prolonged hypophenylalaninaemia seemed to contribute. We have considered the possibility that the rise in IQ was a result of an increase in the propor-tion of children with less severe phenylketonuria, but we have previously failed to find an independent effect of the type of phenylketonuria on outcome once allowance was made for phenylalanine control.'7 Nor are we aware of any important changes in treatment policies or product composition (including tyrosine content) coinciding with the rise in IQ.22 23 On the other hand, nutritional expertise increased rapidly during the 60s and may have benefited children born later.
The IQ data presented here are in accord with those of other countries,2 5 24 although our conclusions about the implications for long term intellectual development are rather less optimistic. The American Collaborative Study, which reported a mean IQ at 4 years on the Stanford Binet (1960 revision) of 103, concluded that the children were making good progress, although this mean was five to seven points below that in unaffected siblings and parents,2 3 4 a reduction similar to that found in the present study. The associations between intellectual progress and the different measures of the quality of treatment were also consistent with data reported by others.2 2427 Nevertheless it was surprising that hypophenylalaninaemia seemed to influence outcome even in children born in the mid 70s when overt phenylalanine deficiency was rarely seen.
In the present study IQ fell linearly by roughly 0-25 SD (four IQ points) for each month between birth and starting treatment, for each 300 [imol/l rise in average phenylalanine concentrations, and for each five months during the first two years during which phenylalanine concentrations were below 120 ,umol/l. Fewer than 10% of subjects achieved the 'best treatment' according to the criteria derived from our study. Although it is not possible to be certain that the association between quality of treatment and IQ is one of cause and effect, this seems the likeliest explanation.
Nevertheless, alternatives have to be considered. For example, even after allowing for the large effect of social class on IQ, less able children might have parents who are less successful at controlling the diet, or less able children might be harder to treat. Another possibility is that phenylalanine control is dependent on the severity of the defect, and that severity affects outcome for reasons other than phenylalanine control.
A previous controlled trial of strict (60-360 ,umol/l) compared with less strict phenylalanine control (361-720 [imolll) failed to show any significant benefit from stricter treatment,28
and resulted in a long held view that it was 'safe' to let phenylalanine concentrations rise to 600-700 [imol/l. The groups in the trial showed a large overlap in phenylalanine concentrations, however, and those who received the stricter diet did have a mean IQ at 3 years of age that was four points above the mean in those who had received the more relaxed diet. In addition, some clinics that achieve strict control of blood phenylalanine concentrations have reported mean IQs that are closer to our revised IQ norms. 26 28 We believe that the therapeutic 'window of safety' is narrow in young children with phenylketonuria who are treated early, and that mild, but important (and probably irreversible) neurological impairment commonly occurs as a result of the persisting disturbance of amino acid metabolism. In children with severe forms of the disorder it is difficult, if not impossible, to maintain phenylalanine concentrations consistently within the therapeutic range and this could well be an important factor in causing neurological damage. Fasting hypotyrosinaemia is also a regular finding in such children. In those with some residual enzyme activity smooth phenylalanine control can be achieved more readily (and fasting hypotryosinaemia is less common), and such children are likely to be over represented among subjects achieving the 'best treatment'.
What recommendations can be made concerning the management of phenylketonuria? First screening, which in the United Kingdom is based on a policy of testing between the sixth and 14th day after birth.'4 16 This comparatively late timing (compared with other national programmes) has the advantage of increasing the difference in phenylalanine concentrations between infants with phenylketonuria and normal infants. Currently the average age at the start of treatment is 14-15 days, which is within the 'ideal' range of less than 21 days. Nevertheless, the importance of swift and efficient procedures for getting blood to the laboratory, analyses done, and children with positive tests diagnosed and treated, needs re-emphasis.
Finally, treatment policy; currently in most clinics the aim in early childhood is to control non-fasting blood phenylalanine concentrations at between 180-480 ,tmol/l. Our findings suggest that this policy may need to be revised to one of controlling phenylalanine concentrations between 120-300 iimol/l. Such a policy, however, runs the risk of causing more frequent hypophenylalaninaemia, which our study suggests is harmful. Attempts at stricter control would certainly require more frequent (twice a week) measurements of blood phenylalanine concentrations, and use of more precise methods of analysis than are often used. In considering the use of a more rigourous dietary regimen the possible risks, scientific uncertainties, cost, and sociological consequences for the children and their families will have to be taken into account. in phenylketonuria.
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